Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D; DeCOG. Schilling B, et al. Among authors: zimmer l. Ann Oncol. 2014 Mar;25(3):747-753. doi: 10.1093/annonc/mdt587. Epub 2014 Feb 6. Ann Oncol. 2014. PMID: 24504444 Free PMC article.
Advances and perspectives in immunotherapy of melanoma.
Schadendorf D, Vaubel J, Livingstone E, Zimmer L. Schadendorf D, et al. Among authors: zimmer l. Ann Oncol. 2012 Sep;23 Suppl 10:x104-8. doi: 10.1093/annonc/mds321. Ann Oncol. 2012. PMID: 22987943 Free article.
[Immunotherapy of melanomas].
Zimmer L, Vaubel J, Schadendorf D. Zimmer L, et al. Hautarzt. 2012 Dec;63(12):952-8. doi: 10.1007/s00105-012-2470-4. Hautarzt. 2012. PMID: 23097082 Review. German.
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Süsskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M. Griewank KG, et al. Among authors: zimmer l. Br J Cancer. 2013 Jul 23;109(2):497-501. doi: 10.1038/bjc.2013.312. Epub 2013 Jun 25. Br J Cancer. 2013. PMID: 23799844 Free PMC article.
Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al.
Schilling B, Sondermann W, Griewank KG, Livingstone E, Zimmer L, Hillen U, Schadendorf D. Schilling B, et al. Among authors: zimmer l. Ann Oncol. 2015 Jan;26(1):250-251. doi: 10.1093/annonc/mdu502. Epub 2014 Oct 29. Ann Oncol. 2015. PMID: 25355721 Free article. No abstract available.
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ugurel S, Loquai C, Kähler K, Hassel J, Berking C, Zimmer L, Haubitz I, Satzger I, Müller-Brenne T, Mikhaimer NC, Becker JC, Kilian KJ, Schadendorf D, Heinzerling L, Kaatz M, Utikal J, Göppner D, Pföhler C, Pflugfelder A, Mössner R, Gutzmer R; Dermatologic Cooperative Oncology Group (DeCOG). Ugurel S, et al. Among authors: zimmer l. Ann Oncol. 2015 Mar;26(3):573-82. doi: 10.1093/annonc/mdu573. Epub 2014 Dec 18. Ann Oncol. 2015. PMID: 25524477 Free article.
551 results